Sikkim Journal

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

March 17
23:50 2020
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

DelveInsight has launched a new report on BPDCN Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “BPDCN Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the BPDCN, historical and forecasted epidemiology as well as the BPDCN market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy of the bone marrow and blood that can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. In fact, skin lesions are present in most patients with BPDCN. These skin lesions are often a deep purple color, and patients often develop multiple lesions. More men than women are diagnosed with BPDCN (~3:1 ratio), and it is most common in patients age 60 years and older. Although BPDCN occurs more frequently in the elderly, the tumor may occur in patients of any age, including pediatric patients. Previously referred to as blastic NK cell leukemia and agranular CD4+/CD56+ hematodermic neoplasm, BPDCN was officially named by the World Health Organization in 2008. BPDCN can also evolve from prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), so patients with those diseases and skin lesions should be specifically evaluated for BPDCN.

 

 

 

Request for:-  BPDCN free sample page

 

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)  Epidemiology 

The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) epidemiology division provide insights about historical and current Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Some of the Report Key facts:-

1. According to a study by Petrella T et al., titled, “Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review”, BPDCN has been described in all age groups but is most common in adults. BPDCN represent 0.7 percent of primary cutaneous skin lymphomas.

2. As per a study published by Aurelia Meloni et al., titled, “Review on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with data on clinics, and the genes involved”, the incidence of this neoplasm accounts for 0.4% of all hematologic neoplasms, 0.7% of the primary cutaneous lymphomas, and less than 1% of all acute leukemias (Facchetti et al., 2008; Riaz et al., 2014; Rossi et al., 2006; Pagano et al., 2013)

 

Report Key Benefits

1. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market report covers a descriptive overview and comprehensive insight of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) epidemiology Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market report provides insights on the current and emerging therapies. 

3. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market report offers a global historical and forecasted market covering drug outreach in 7 MM.

4. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease market.

 

Some of the key companies working on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) that are given below-

  1. Stemline Therapeutics Inc.
  2. Immunogen Pharma Co. 
  3. Cellectis Pharma Co. 

Name of covered Drugs are given below.

  1. Elzonris (Tagraxofusp-erzs)
  2. IMGN632
  3. UCART123

Table of Contents

1. Key Insights

2. Executive Summary of BPDCN

3. Competitive Intelligence Analysis for BPDCN

4. BPDCN: Market Overview at a Glance

5. BPDCN: Disease Background and Overview

6. Patient Journey

7. Cold Agglutinin Disease (CAD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of BPDCN Treatment

11. Marketed Products

12. Emerging Therapies

13. BPDCN: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of BPDCN

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this BPDCN market report?

  • The report will help in developing business strategies by understanding trends shaping and driving the BPDCN market
  • To understand the future market competition in the BPDCN market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for BPDCN  in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for BPDCN market
  • To understand the future market competition in the BPDCN market

Related Reports:-

  1. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology Forecast 2030
  2. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Pipeline Insights, 2020

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles